Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Ranbaxy Laboratories Inc. v. First Databank, Inc.
Case Number:
3:13-cv-00859
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 10, 2015
First Databank Escapes Ranbaxy's Acne Med Libel Suit
A Florida federal judge on Tuesday threw out a libel suit brought by Ranbaxy Laboratories Inc., ruling that medical publisher First Databank Inc. didn't incorrectly list substitutes for the acne medication Absorica in a drug database.
-
July 18, 2013
Ranbaxy Sues First Databank For Trade Libel Over Acne Drug
Ranbaxy Laboratories Inc. hit drug information publisher First Databank Inc. with a trade libel suit in Florida federal court Wednesday, saying FDB's database falsely indicates that Ranbaxy's Absorica acne drug can be safely substituted with certain other drugs, causing it more than $15 million in damages.